Evidence map›Paper›PMID 37894139›Full record

ArticleMicroorganisms2023

Estimated Incidence of Symptomatic Lyme Borreliosis Cases in Lublin, Poland in 2021.

Emily Colby, Julia Olsen, Frederick J Angulo, Patrick Kelly, Kate Halsby, Andreas Pilz, Urszula Sot, Tomasz Chmielewski, Katarzyna Pancer, Jennifer C Moïsi and 2 more

Abstract read
In one paragraph

Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. High Prevalence of Borrelia burgdorferi Antibodies in Jaworzno, Poland: A Retrospective Study Revealing Endemic Lyme Borreliosis.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emily ColbyVaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.
Julia OlsenVaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.ORCID 0000-0002-7781-4817
Frederick J AnguloVaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.ORCID 0000-0002-3120-7704
Patrick KellyVaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.ORCID 0000-0002-5155-6741
Kate HalsbyPfizer Vaccines, Tadworth, Surrey KT20 7NS, UK.
Andreas PilzVaccines, Pfizer Corporation Austria, 1210 Vienna, Austria.ORCID 0000-0002-6394-3845
Urszula SotVaccine Medical Affairs, Pfizer Poland Inc., 02-092 Warsaw, Poland.
Tomasz ChmielewskiNational Institute of Public Health, 00-791 Warsaw, Poland.
Katarzyna PancerNational Institute of Public Health, 00-791 Warsaw, Poland.ORCID 0000-0003-3665-5765
Jennifer C MoïsiPfizer Vaccines, 75014 Paris, France.
Luis JodarVaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.
James H StarkVaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Cambridge, MA 02139, USA.

Funding

Pfizer (United States) N/AValneva (United States) N/A
6 · The paper itself

Abstract

Lyme borreliosis (LB), the most common tick-borne disease in Europe, is endemic to Poland. Despite public health surveillance with mandatory reporting of LB cases by physicians and laboratories, many symptomatic LB cases are not included in surveillance in Poland. We estimated the extent of the under-ascertainment of symptomatic LB cases via surveillance in the Polish province of Lublin to better understand Poland's LB burden. The number of incident symptomatic LB cases in Lublin in 2010 was estimated from two seroprevalence studies conducted among adults in Lublin, as well as estimates of the proportion of asymptomatic LB cases and the duration of LB antibody persistence. The estimated number of incident symptomatic LB cases was compared to the number of surveillance-reported cases in Lublin to derive an under-ascertainment multiplier. This multiplier was applied to the number of surveillance-reported cases in 2021 to estimate the number and population-based incidence of symptomatic LB cases in Lublin in 2021. We estimate that there are 5.9 symptomatic LB cases for every surveillance-reported LB case in Lublin. Adjusting for under-ascertainment, the estimated number of symptomatic LB cases in Lublin in 2021 was 6204 (population-based incidence: 467.6/100,000). After adjustment for under-ascertainment, the incidence of symptomatic LB in Lublin, Poland, is high.

Indexed as

incidenceLyme borreliosisPolandseroprevalencesurveillancetick-borne disease

Identifiers

PMID37894139
PMCPMC10608808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.